Fig. 1

TNBC: The current and upcoming therapeutic strategies targeting the mutant proteins or pathways to enable tailored-therapeutics. Therapeutics target at genetic alterations include defects in DNA damage repair, TP53 mutations, activation of PI3K pathway, EGFR amplification/mutations, activation of RAF-MEK signaling, and Rb loss. These genetic alterations were summarized in the white boxes of the diagram. Potential therapeutic strategies were depicted in red boxes